Answers are grounded in this paper and cite their sources.
Ed Silverman looks into the ongoing battle over whether biosimilars should have the same name as brand name biologics
No takes yet. Share an insight, caveat, or question.
Edwin K. Silverman (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: